BOLD Stock Forecast 2025-2026
Distance to BOLD Price Targets
BOLD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Audentes (BOLD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BOLD and similar high-potential opportunities.
Latest BOLD Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, BOLD has a neutral consensus with a median price target of $15.00 (ranging from $15.00 to $15.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.42, the median forecast implies a 956.3% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BOLD Analyst Ratings
BOLD Price Target Range
Latest BOLD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BOLD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 13, 2024 | Guggenheim | Yige Guo | Neutral | Downgrade | $0.00 |
| Apr 22, 2024 | Guggenheim | Yige Guo | Buy | Initiates | $24.00 |
| Apr 22, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $20.00 |
| Apr 22, 2024 | Leerink Partners | Michael Cherny | Outperform | Initiates | $25.00 |
| Dec 9, 2019 | Evercore ISI Group | In-Line | Downgrade | $0.00 | |
| Dec 6, 2019 | JP Morgan | Neutral | Downgrade | $0.00 | |
| Dec 4, 2019 | Chardan Capital | Neutral | Downgrade | $60.00 | |
| Dec 4, 2019 | SVB Leerink | Market Perform | Downgrade | $0.00 | |
| Dec 3, 2019 | BMO Capital | Market Perform | Downgrade | $60.00 | |
| Dec 3, 2019 | Raymond James | Market Perform | Downgrade | $0.00 | |
| Dec 3, 2019 | Guggenheim | Neutral | Downgrade | $0.00 | |
| Dec 3, 2019 | Piper Sandler | Neutral | Downgrade | $60.00 | |
| Dec 3, 2019 | HC Wainwright & Co. | Neutral | Downgrade | $60.00 | |
| Dec 3, 2019 | Citigroup | Neutral | Upgrade | $60.00 | |
| Dec 3, 2019 | Piper Jaffray | Neutral | Downgrade | $0.00 | |
| Dec 3, 2019 | Baird | Neutral | Upgrade | $0.00 | |
| Dec 3, 2019 | Wedbush | Neutral | Downgrade | $0.00 | |
| Nov 19, 2019 | Evercore ISI Group | Outperform | Upgrade | $40.00 | |
| Oct 3, 2019 | Baird | Underperform | Initiates | $10.00 | |
| Sep 3, 2019 | Chardan Capital | Buy | Maintains | $50.00 |
Boundless Bio Inc. (BOLD) Competitors
The following stocks are similar to Audentes based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Boundless Bio Inc. (BOLD) Financial Data
Boundless Bio Inc. has a market capitalization of $31.67M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -48.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Boundless Bio Inc. (BOLD) Business Model
About Boundless Bio Inc.
Develops therapies for cancer treatment.
The company focuses on creating precision medicines that specifically target extrachromosomal DNA (ecDNA) involved in cancer progression. By addressing oncogenic amplification, Boundless Bio generates revenue through the development and commercialization of innovative cancer therapies that meet significant unmet medical needs.
Boundless Bio is positioned at the forefront of biotechnology, contributing to advancements in genetic research and targeted cancer therapeutics. Its pioneering research emphasizes personalized medicine, aiming to transform healthcare and improve outcomes for cancer patients with limited treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Mr. Zachary Hornby
Country
United States
IPO Year
N/A
Website
boundlessbio.comBoundless Bio Inc. (BOLD) Latest News & Analysis
Boundless Bio (Nasdaq: BOLD) will have CEO Zachary Hornby speak at Needham's Virtual Healthcare Conference, focusing on therapies for oncogene amplified cancers.
Boundless Bio's participation in the Needham Conference highlights its strategic visibility and potential for investment interest, particularly in innovative cancer therapies, which can impact stock performance.
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
23 days agoBoundless Bio (Nasdaq: BOLD) is advancing its BBI-355 trial in oncogene amplified cancers, with proof-of-concept data expected in H2 2025. The company has $152M in cash, funding operations into 2027.
Boundless Bio's ongoing trials and cash position suggest potential for future growth and product development, impacting stock value and investor confidence in the oncology sector.
Boundless Bio (Nasdaq: BOLD) will have CEO Zachary Hornby speak at Leerink's Global Healthcare Conference on March 12, 2025, at 11:20 a.m. in Miami, FL, discussing their ecDNA oncology therapies.
Boundless Bio's participation in a notable healthcare conference highlights its visibility and potential investor interest, especially in innovative cancer therapies, which can impact stock performance.
Dr. Doebele brings over 15 years of oncology drug development experience as a Chief Medical Officer and clinical researcher at top cancer centers.
Dr. Doebele's extensive experience in oncology drug development may enhance the credibility and potential success of the company's pipeline, influencing investor confidence and stock performance.
The Russell 2000 Index increased by 0.4% in the first week of 2025, suggesting the potential onset of the "January Effect" following its worst month.
The Russell 2000's early gains suggest a potential recovery trend, signaling increased investor confidence and a favorable market environment for small-cap stocks.
The company will not proceed with BBI-825 in the STARMAP trial and is advancing a third ecDTx program, extending its operating runway into 2027. Key executives are stepping down.
The decision to halt the BBI-825 trial may indicate strategic shifts, impacting future growth potential. Leadership changes could affect investor confidence and company direction.
Frequently Asked Questions About BOLD Stock
What is Boundless Bio Inc.'s (BOLD) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Boundless Bio Inc. (BOLD) has a median price target of $15.00. The highest price target is $15.00 and the lowest is $15.00.
Is BOLD stock a good investment in 2025?
According to current analyst ratings, BOLD has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BOLD stock?
Wall Street analysts predict BOLD stock could reach $15.00 in the next 12 months. This represents a 956.3% increase from the current price of $1.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Boundless Bio Inc.'s business model?
The company focuses on creating precision medicines that specifically target extrachromosomal DNA (ecDNA) involved in cancer progression. By addressing oncogenic amplification, Boundless Bio generates revenue through the development and commercialization of innovative cancer therapies that meet significant unmet medical needs.
What is the highest forecasted price for BOLD Boundless Bio Inc.?
The highest price target for BOLD is $15.00 from at , which represents a 956.3% increase from the current price of $1.42.
What is the lowest forecasted price for BOLD Boundless Bio Inc.?
The lowest price target for BOLD is $15.00 from at , which represents a 956.3% increase from the current price of $1.42.
What is the overall BOLD consensus from analysts for Boundless Bio Inc.?
The overall analyst consensus for BOLD is neutral. Out of 13 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are BOLD stock price projections?
Stock price projections, including those for Boundless Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.